GlassScriptPhysician profile
Jennifer Rs Gordon
NPI 1073748281
$150,263.92
in general payments reported to CMS, 2019-2025
36 companies · $15K in 2025
The $15K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,391 · 2020: $20K · 2021: $8,258 · 2022: $12K · 2023: $71K · 2024: $18K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Food and Beverage: $9,176 · Travel and Lodging: $3,351 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,701.62 |
| Food and Beverage | $9,175.85 |
| Travel and Lodging | $3,350.56 |
| Education | $269.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $133,865.14 | 2019-2025 | Aklief, Twyneo, Epsolay |
| Merz North America, INC. | $4,005.11 | 2019-2025 | |
| Abbvie INC. | $2,747.11 | 2019-2025 | |
| Janssen Biotech, INC. | $2,203.46 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $689.36 | 2019-2025 | Dupixent, Libtayo |
| Biofrontera INC. | $668.51 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $668.09 | 2019-2025 | Winlevi, Absorica Ld, Odomzo |
| Pfizer INC. | $575.87 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $536.91 | 2019-2025 | Cabtreo, Arazlo, Jublia |
| Verrica Pharmaceuticals INC. | $500.00 | 2024 | Ycanth |
| Lilly USA, LLC | $453.39 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $395.63 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $360.37 | 2019-2025 | |
| Ucb, INC. | $339.15 | 2022-2025 | Bimzelx, Cimzia |
| Vyne Pharmaceuticals INC. | $264.79 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $252.36 | 2019-2025 | |
| Amgen INC. | $249.06 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $240.74 | 2019-2025 | Adbry |
| Revance Therapeutics, INC. | $212.42 | 2025 | Daxxify |
| Allergan, INC. | $175.66 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $145.55 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $132.75 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $116.09 | 2019 | |
| Arcutis Biotherapeutics, INC. | $95.66 | 2023-2025 | Zoryve |
| Almirall LLC | $66.97 | 2019-2024 | Seysara |
| Organon LLC | $50.53 | 2025 | Vtama |
| Dermavant Sciences, INC. | $43.86 | 2023 | Vtama |
| Journey Medical Corporation | $42.13 | 2022 | |
| Botanix Sb INC | $31.70 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.98 | 2024 | Spevigo |
| Celgene Corporation | $21.89 | 2019 | |
| Aclaris Therapeutics, INC. | $20.91 | 2019 | |
| Epi Health, LLC | $20.57 | 2019 | |
| Encore Dermatology INC. | $19.43 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $16.30 | 2020 | |
| Prugen, INC. Pharmaceuticals | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.